MX2019006694A - Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. - Google Patents

Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.

Info

Publication number
MX2019006694A
MX2019006694A MX2019006694A MX2019006694A MX2019006694A MX 2019006694 A MX2019006694 A MX 2019006694A MX 2019006694 A MX2019006694 A MX 2019006694A MX 2019006694 A MX2019006694 A MX 2019006694A MX 2019006694 A MX2019006694 A MX 2019006694A
Authority
MX
Mexico
Prior art keywords
oxabicycloheptanes
modulation
immune response
subject
administering
Prior art date
Application number
MX2019006694A
Other languages
English (en)
Inventor
S Kovach John
Zhuang Zhengping
Chun Winson Ho Sze
Wang Herui
Lu Rongze
Original Assignee
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Inc filed Critical Lixte Biotechnology Inc
Publication of MX2019006694A publication Critical patent/MX2019006694A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un método de tratar un sujeto afectado con cáncer que comprende administrar al sujeto una cantidad eficaz de un inhibidor de PP2A.
MX2019006694A 2016-12-08 2017-12-08 Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. MX2019006694A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662497949P 2016-12-08 2016-12-08
US201762465001P 2017-02-28 2017-02-28
US201762545373P 2017-08-14 2017-08-14
PCT/US2017/065270 WO2018107004A1 (en) 2016-12-08 2017-12-08 Oxabicycloheptanes for modulation of immune response

Publications (1)

Publication Number Publication Date
MX2019006694A true MX2019006694A (es) 2019-08-21

Family

ID=62491355

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006694A MX2019006694A (es) 2016-12-08 2017-12-08 Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.

Country Status (13)

Country Link
US (1) US20200069680A1 (es)
EP (2) EP3551629B1 (es)
JP (2) JP7246309B2 (es)
KR (2) KR20240042151A (es)
CN (2) CN116585480A (es)
AU (1) AU2017370731B2 (es)
BR (1) BR112019011627A2 (es)
CA (1) CA3046515A1 (es)
DK (1) DK3551629T3 (es)
ES (1) ES2970913T3 (es)
IL (2) IL290857B2 (es)
MX (1) MX2019006694A (es)
WO (1) WO2018107004A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
AU2016263079B2 (en) 2015-05-15 2019-08-15 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs
KR20210019857A (ko) 2019-08-13 2021-02-23 주식회사 엘지화학 전극 스크랩 재활용 방법 및 이를 이용한 전극 제조 방법
WO2024097784A2 (en) * 2022-11-03 2024-05-10 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for treating refractory cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002242175A1 (en) * 2001-02-16 2002-09-04 Brigham And Women's Hospital Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
AU2008214299B2 (en) * 2007-02-06 2014-01-09 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
WO2014005080A1 (en) * 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
WO2014005084A1 (en) * 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
EP2983661B1 (en) * 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
WO2015073802A1 (en) 2013-11-15 2015-05-21 Lixte Biotechnology, Inc. Protein phosphatase inhibitors that cross the blood brain barrier
WO2015196073A1 (en) * 2014-06-20 2015-12-23 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
AU2015314753A1 (en) * 2014-09-12 2017-04-06 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
AU2016249395B2 (en) * 2015-04-17 2022-04-07 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-PD-1 antibody and another antibody
AU2016263079B2 (en) 2015-05-15 2019-08-15 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs

Also Published As

Publication number Publication date
EP3551629A4 (en) 2020-07-29
CA3046515A1 (en) 2018-06-14
IL290857A (en) 2022-04-01
AU2017370731A1 (en) 2019-07-04
DK3551629T3 (da) 2024-02-12
JP7246309B2 (ja) 2023-03-27
CN110234647B (zh) 2023-05-23
JP2020502094A (ja) 2020-01-23
IL267134A (en) 2019-08-29
CN116585480A (zh) 2023-08-15
AU2017370731B2 (en) 2022-06-02
KR20190098995A (ko) 2019-08-23
EP4324477A2 (en) 2024-02-21
EP4324477A3 (en) 2024-05-22
KR20240042151A (ko) 2024-04-01
ES2970913T3 (es) 2024-05-31
BR112019011627A2 (pt) 2019-11-12
IL290857B2 (en) 2023-03-01
EP3551629A1 (en) 2019-10-16
CN110234647A (zh) 2019-09-13
IL290857B (en) 2022-11-01
IL267134B (en) 2022-04-01
WO2018107004A1 (en) 2018-06-14
JP2023036999A (ja) 2023-03-14
EP3551629B1 (en) 2023-11-15
US20200069680A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
MX2018016193A (es) Métodos para el tratamiento del cáncer de ovario.
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
PH12016501601A1 (en) Cyclopropylamines as lsd1 inhibitors
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
BR112017027990A2 (pt) modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2017001154A (es) Metodos y combinaciones terapeuticas para tratar tumores.
TW201613860A (en) Cyclopropylamines as LSD1 inhibitors
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA033325B1 (ru) Ингибиторы бромодомена
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
EA201991818A1 (ru) Лечение рака
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017009246A (es) Farmaco de combinacion.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
NZ722600A (en) Methods of treating mild brain injury
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين